In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli

Pharmacotherapy

Volumn 28, Issue 3, 2008, Pages 295-300

  Cha, Raymond ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Cefepime; Combination; ESBL; Escherichia coli; Extended spectrum lactamase; Imipenem; Klebsiella pneumoniae; Tigecycline

Indexed keywords

CEFEPIME; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; TIGECYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; GENTAMICINS; IMIPENEM; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 40149087719     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.3.295     Document Type: Article

References (19)

1. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY antimicrobial surveillance program (1997-2001). Semin Respir Crit Care Med 2003;24:121-34.
2. Moland ES, Hanson ND, Black JA, Hossain A, Song W, Thomson KS. Prevalence of newer β-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. J Clin Microbiol 2006;44:3318-24.
3. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51.
4. Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001;21:583-92.
5. Bush K. New β-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2002;32:1085-9.
6. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis 2004;39:31-7.
7. Jones RN, Biedenbach DJ, Gales AC. Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int J Antimicrob Agents 2003;21:1-7.
8. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics- pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob Agents Chemother 2003;47:1643-6.
9. Sader HS, Hsiung A, Fritsche TR, Jones RN. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis 2007;57:341-4.
10. Labombardi VJ, Rojtman A, Tran K. Use of cefepime for the treatment of infections caused by extended spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Diagn Microbiol Infect Dis 2006;56:313-15.
11. Ramphal R, Ambrose PG. Extended-spectrum β-lactamases and clinical outcomes: current data. Clin Infect Dis 2006;42:S164-72.
12. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Clinical implications of extended-spectrum β-lactamase (ESBL)-producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infect 2005;51:211-17.
13. Reese AM, Frei CR, Burgess DS. Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and celepime against extended-spectrum β-lactamase-producing organisms. Int J Antimicrob Agents 2005;26:114-19.
14. Song W, Moland ES, Hanson ND, Lewis JS, Jorgensen JH, Thomson KS. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol 2005;43:4891-4.
15. Grover SS, Sharma M, Chattopadhya D, Kapoor H, Pasha ST, Singh G. Phenotypic and genotypic detection of ESBL-mediated cephalosporin resistance in Klebsiella pneumoniae: emergence of high resistance against cefepime, the fourth generation cephalosporin. J Infect 2006;53:279-88.
16. Hoban DJ, Bouchillon SK, Dowzicky MJ. Antimicrobial susceptibility of extended-spectrum β-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn Microbiol Infect Dis 2007;57:423-8.
17. Nathisuwan S, Burgess DS, Lewis JS II. Extended-spectrum β-lactamases: epidemiology, detection, and treatment. Pharmacotherapy 2001;21:920-8.
18. Clinical and Laboratory Standards Institute. Performance standards ior antimicrobial disk susceptibility tests, 9th ed. Approved standard M2-A9. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
19. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001;45:3548-54.